Cellectar Biosciences/$CLRB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cellectar Biosciences
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Ticker
$CLRB
Sector
Primary listing
Employees
11
Headquarters
Website
CLRB Metrics
BasicAdvanced
$20m
-
-$6.35
0.43
-
Price and volume
Market cap
$20m
Beta
0.43
52-week high
$10.19
52-week low
$2.20
Average daily volume
292k
Financial strength
Current ratio
1.901
Quick ratio
1.713
Long term debt to equity
32.41
Total debt to equity
32.41
Profitability
EBITDA (TTM)
-22.162
Management effectiveness
Return on assets (TTM)
-102.96%
Return on equity (TTM)
-290.42%
Valuation
Price to book
3.74
Price to tangible book (TTM)
3.74
Price to free cash flow (TTM)
-0.438
Free cash flow yield (TTM)
-228.23%
Free cash flow per share (TTM)
-5.66
Growth
Earnings per share change (TTM)
-72.88%
3-year earnings per share growth (CAGR)
-62.28%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs